STOCK TITAN
  1. Home
  2. News
  3. NMRD

Nemaura Med Inc - NMRD STOCK NEWS

Welcome to our dedicated page for Nemaura Med news (Ticker: NMRD), a resource for investors and traders seeking the latest updates and insights on Nemaura Med stock.

Nemaura Medical Inc. (NMRD) is a pioneering medical technology company specializing in the discovery, development, and commercialization of diagnostic medical devices. Founded in 2009 and based in New York, New York, Nemaura Medical is committed to enhancing the healthcare industry with innovative solutions.

The company's flagship product is SugarBEAT, a non-invasive continuous glucose monitoring device designed for individuals with Type I and Type II diabetes, as well as those at risk of developing diabetes. SugarBEAT offers real-time glucose readings, helping users manage their health more effectively without the need for painful finger-pricking.

In addition to SugarBEAT, Nemaura Medical has entered a strategic license agreement with Healthimation, LLC. This agreement allows the company to offer an intensive medical diabetes and weight management program tailored for Type 2 diabetes, prediabetes, and general wellness. The program includes the innovative Why Wait app, which integrates licensed trademarks and provides users with a comprehensive health management tool.

The company prides itself on its strong partnerships and continuous advancements in medical technology. Recent projects and developments at Nemaura Medical reflect its dedication to improving patient outcomes and expanding its product portfolio.

For investors seeking timely updates and insights into Nemaura Medical's activities, the company regularly publishes news and financial summaries. Stay informed about the latest corporate highlights and innovations from Nemaura Medical by visiting their official website or contacting their investor relations team.

News

Important Update on Listing Status and Strategic Direction

Rhea-AI Summary
Nemaura Medical Inc. (NMRD) to Move from Nasdaq to OTC Markets: Strategic Decision and Future Outlook
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-31.91%
Tags
none
-
News

Nemaura Medical Inc. Receives Positive Nasdaq Listing Decision

Rhea-AI Summary
Nemaura Medical Inc. (NASDAQ: NMRD) has been granted continued listing on The Nasdaq Capital Market until April 1st, 2024, by the Nasdaq Hearings Panel. The company is focused on developing a non-invasive glucose sensor and digital healthcare programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.57%
Tags
none
-
News

Nemaura Medical Inc. Secures $10 Million Non-Dilutive Credit Facility to Fuel Strategic Growth

Rhea-AI Summary
Nemaura Medical Inc. (NMRD) secures a $10 million credit facility to support strategic growth plans, minimizing dilution and preserving shareholder value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.93%
Tags
none
News

Nemaura Launches Direct to Consumer Offering of Metabolic Health Program in Combination with GLP-1 Weight Loss Drugs

Rhea-AI Summary
Nemaura Medical: UK Launches Groundbreaking Metabolic Health and Weight Management Program Integrating Continuous Glucose Monitoring and GLP-1 Agonists
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.08%
Tags
none
-
News

Nemaura Medical Reports Fiscal Second Quarter 2024 Results and Provides Business Update

Rhea-AI Summary
Nemaura Medical, Inc. (Nasdaq: NMRD) released its financial results for the quarter ended September 30, 2023, and provided a business update. The company continued to support its UK licensee for sensor reimbursement, advanced development of BEATdiabetes, and received approval for marketing sugarBEAT in Saudi Arabia. Financially, R&D expenses increased, while net loss decreased, with cash and cash equivalents at approximately $4.4m.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.08%
Tags
earnings
-
News

Nemaura Medical Announces Appointment of Mr Nikolai Rozanov as Strategic Adviser in Artificial Intelligence, to Assist in Development of its AI Health Coach, and Strengthen Outcomes in its CGM Based Metabolic and Type 2 Diabetes Programs.

Rhea-AI Summary
Nemaura Medical appoints Nikolai Rozanov as strategic adviser in AI development, solidifying the company's expertise in the growing AI sector. This will allow for the integration of data from its CGM to create tailored programs and personalized recommendations. AI-based models have a vital role in the healthcare and lifestyle sector.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.39%
Tags
management AI
News

Nemaura Medical to Present at the Maxim Group Emerging Growth in A.I. Conference

Rhea-AI Summary
Nemaura Medical CEO to present business updates at Maxim Group conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.2%
Tags
conferences acquisition
-
News

Nemaura Medical Provides Update on Nasdaq Compliance Status and Process

Rhea-AI Summary
Nemaura Medical, Inc. provides update on compliance with Nasdaq listing standards, anticipates delisting determination after grace periods expire. Company plans to request a hearing before a Nasdaq Hearings Panel for possible extension. Continues to focus on business expansion and product launch in Saudi Arabia.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2%
Tags
none
-
News

Nemaura Medical Announces Interim Results from its Collaboration with the UK’s National Health Service on its Metabolic Health & Weight Loss Program

Rhea-AI Summary
Nemaura Medical announces interim results from its metabolic health program, showing weight loss of 2.9KG on average after 20 weeks. Retention rate of 32.5% and 64% of active participants likely to continue the program. Company plans to offer low-cost CGM-embedded program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
28.86%
Tags
none
News

Nemaura Medical Announces Participation at HLTH 2023, Las Vegas

Rhea-AI Summary
Nemaura Medical to participate at HLTH 2023 conference, showcasing their wearable diagnostic device and diabetes management program integration
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.5%
Tags
none

FAQ

What is the current stock price of Nemaura Med (NMRD)?

The current stock price of Nemaura Med (NMRD) is $0.0002 as of March 25, 2025.

What is the market cap of Nemaura Med (NMRD)?

The market cap of Nemaura Med (NMRD) is approximately 8.1K.

What is Nemaura Medical Inc.?

Nemaura Medical Inc. is a medical technology company that develops and commercializes diagnostic medical devices, including the non-invasive continuous glucose monitoring device SugarBEAT.

What products does Nemaura Medical Inc. offer?

Nemaura Medical offers SugarBEAT, a non-invasive glucose monitoring device, and the Why Wait app, part of their diabetes and weight management program.

Where is Nemaura Medical Inc. based?

Nemaura Medical Inc. is based in New York, New York.

When was Nemaura Medical Inc. founded?

Nemaura Medical Inc. was founded in 2009.

What is SugarBEAT?

SugarBEAT is a non-invasive continuous glucose monitoring device developed by Nemaura Medical for managing diabetes.

How does SugarBEAT help diabetic patients?

SugarBEAT provides real-time glucose readings without the need for finger-pricking, helping diabetic patients manage their condition more effectively.

What is the Why Wait app?

The Why Wait app is part of Nemaura Medical's diabetes and weight management program, offering tools and resources for Type 2 diabetes, prediabetes, and general wellness.

Who are Nemaura Medical's partners?

Nemaura Medical has a license agreement with Healthimation, LLC, among other strategic partners.

Where can I find more information about Nemaura Medical Inc.?

More information can be found on Nemaura Medical's official website or by contacting their investor relations team.

How can investors stay updated on Nemaura Medical Inc.'s activities?

Investors can stay updated by visiting Nemaura Medical's website and reviewing their latest news and financial summaries.
Stock NMRD logo
Nemaura Med Inc

Nasdaq:NMRD

NMRD Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

NMRD Stock Data

8.07k
17.26M
57.24%
2.1%
0.18%
Medical Devices
Healthcare
Link
United States
New York